CD19 and acute lymphoblastic leukemia: In recent years, cellular immunotherapy of CD19-directed chimeric antigen receptor (CAR) T cells (CAR-T) has shown impressive therapeutic responses in R/R B-ALL patients, with high CR rates ranging from 70% to 94%, dramatically altering the treatment strategy for R/R ALL (13–17).